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KPC Type β β-
Lactamase, Rural
Pennsylvania 
To the Editor: Rural counties
have been defined as those lacking a
metropolitan center that has a popula-
tion >50,000 persons (1). Little is
known about antimicrobial drug
resistance in such communities in the
United States. Stevenson and col-
leagues (2) recently evaluated antimi-
crobial drug–resistant gram-positive
infections in rural hospitals in Idaho
and Utah. These researchers found
that both methicillin-resistant
Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococci
occurred in such settings, although
some of the MRSA strains were
probably community associated.
Comparable studies on multidrug-
resistant gram-negative infections
have not been performed, to our
knowledge.
Klebsiella pneumoniae producing
a broad-spectrum β-lactamase, KPC,
has been described in tertiary care
centers and other metropolitan hospi-
tals in New York City. Examples have
also been found in similar settings in
Boston, New Jersey, Maryland, and
North Carolina (3–5). The carbapen-
ems (such as imipenem and meropen-
em) are typically the most active
antimicrobial agents against the
Enterobacteriaceae. The KPC β-lac-
tamases inactivate carbapenems and
all other β-lactam antimicrobial
drugs. Unfortunately, bacteria produc-
ing the KPC type β-lactamases are
typically also resistant to trimetho-
prim/sulfamethoxazole, quinolones,
and aminoglycosides, thereby making
these pathogens truly multidrug
resistant.
We describe a patient with KPC-
producing K. pneumoniae in a rural
setting in central-west Pennsylvania.
The case highlights the potential for
multidrug-resistant gram-negative
organisms to occur outside their
previously recognized settings in
large metropolitan centers.
The patient was a 76-year-old
woman who lived alone, closely
attended by her daughter, in a small,
central Pennsylvania community, 95
miles from a metropolitan center with
a population of >50,000. Her medical
history included a seizure disorder,
hypertension, osteoarthritis of the
knees, obesity, osteoporosis, and total
hysterectomy. A month before isola-
tion of the KPC-producing K. pneu-
moniae, the patient had a 3-day hospi-
tal admission to a 200-bed hospital in
the nearest metropolitan center (popu-
lation 7,000) after a fall. She was dis-
charged to a local nursing home for
rehabilitation. She is not known to
have visited or been hospitalized in
New York, Philadelphia, or New
Jersey, nor did she share a room with
a patient known to have been hospital-
ized in these areas. She had no known
animal contact. She had received
trimethoprim/sulfamethoxazole and
levofloxacin for treatment for urinary
tract infections in the month before
the KPC-producing strain was isolat-
ed. She was readmitted to the 200-bed
hospital with pyelonephritis in August
2005. Cultures of urine grew K. pneu-
moniae; the organism was resistant to
all β-lactam antimicrobial drugs test-
ed, including cefepime, ceftriaxone,
piperacillin/tazobactam, imipenem,
fluoroquinolones, trimethoprim/sul-
famethoxazole, gentamicin, and
tobramycin. The patient received ther-
apy with amikacin in combination
with cefepime, ertapenem, or tigecy-
cline at different times over the fol-
lowing 4 weeks. Her symptoms
improved, although her urine
remained colonized with the mul-
tidrug-resistant  K. pneumoniae. In
October 2005, Clostridium difficile
infection developed, accompanied by
deep venous thrombosis and gastroin-
testinal bleeding, and the patient died.
Multiple blood cultures collected
before her death were negative,
although the urine was persistently
colonized with the multidrug-resistant
K. pneumoniae.
The organism was referred to a
research laboratory in a metropolitan
center  ≈100 miles away. Molecular
analysis of the mechanisms of resist-
ance was performed by using previ-
ously described methods (6). This
analysis showed that the K. pneumo-
niae isolate produced the extended-
spectrum  β-lactamase (ESBL) SHV-
11 and the carbapenemase KPC-2.
Since community-associated
ESBL-producing organisms have
been described in Canada and Europe
(7,8), acquisition or in vivo develop-
ment of ESBL and KPC-producing
strains could have occurred outside of
the healthcare setting. More likely, the
patient acquired her almost complete-
ly resistant gram-negative organism
in the rural hospital or her local nurs-
ing home. To our knowledge, no other
clinical isolates with the same antimi-
crobial phenotype have been seen in
patients in either setting before or
after the patient’s admission. An
unsuspected reservoir of patients col-
onized with antimicrobial drug–resist-
ant gram-negative organisms may
exist (9). Ideally, an epidemiologic
investigation at both the hospital and
nursing home would have been per-
formed, but facilities for an investiga-
tion involving use of selective micro-
biologic media and assessment of gas-
trointestinal carriage of resistant
organisms are not typically available
in a rural setting. Indeed, most rural
hospitals do not even use routine diag-
nostic tests for detecting resistant
gram-negative organisms such as
ESBL producers (10).
Although much attention has been
focused on the progression of antimi-
crobial drug resistance in gram-posi-
tive organisms, the development of
alternative antimicrobial agents such
as linezolid and daptomycin may mit-
igate the disastrous scenario of com-
plete resistance to all commercially
available antimicrobial agents.
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multidrug-resistant gram-negative
pathogens, and enhanced measures
are needed to prevent spread of these
organisms. Agreater understanding of
the modes of spread and acquisition of
these organisms is essential for effec-
tive control of this problem. We have
reported just 1 case of infection with
an almost completely resistant gram-
negative organism. This case expands
the known geographic spread of
organisms with this resistance prob-
lem. This case also underscores the
importance of studying the epidemiol-
ogy of antimicrobial drug resistance
in gram-negative organisms in the
rural setting as well as in large metro-
politan centers. Dissemination of
knowledge regarding appropriate
antimicrobial drug susceptibility test-
ing for resistant organisms is also
needed.
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Severe Pneumonia
and Human
Bocavirus in Adult
To the Editor: The newly identi-
fied human bocavirus (hBoV), a
member of the Parvovirus family, is
suspected to infect the cells of the res-
piratory tract and thus may be an etio-
logic agent of respiratory disease in
humans (1). Although Koch postu-
lates have not been fulfilled for HboV,
it appears likely to cause a substantial
number of respiratory tract infections,
at least in children (2,3). We describe
a case of severe atypical pneumonia
associated with hBoV DNAin a bron-
choalveolar lavage (BAL) sample
from an adult.
The patient was a 28-year-old
Caucasian woman with an angioim-
munoblastic T–non-Hodgkin lym-
phoma (NHL) that changed into a
highly malignant blastic B-cell lym-
phoma (T-cell–rich B-NHL state I
with 70% CD20+ cells, initial stage
IIIB). The patient was previously
treated with vincristine and pred-
nisone, followed by chemotherapy
according to the R-CHOEP-14 proto-
col (3 cycles) (November 2003
through January 2004). From January
through February 2004, chemothera-
py was combined with antimicrobial
drug therapy according to the R-
DHAP protocol (which includes dex-
amethasone, the chemotherapy drugs
cytarabine and cisplatin, and the mon-
oclonal antibody drug rituximab) for
persisting symptoms from the B-cell
lymphoma. This regimen was fol-
lowed by a therapy switch to alem-
tuzumab with ifosfamid, carboplatin,
and etoposide (March 2004), which
led to a therapy-induced leukopenia,
thrombocytopenia, and high fever
>40°C by the end of March and the
beginning of April 2004. In May
2004, a second round of alemtuzumab
with ifosfamid, carboplatin, and
etoposide chemotherapy was initiated.
In June 2004, a therapy-induced
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